Asia Pacific Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

Description

List of Tables

The Asia Pacific lung cancer therapy market was valued at US$ 3,778.03 million in 2022 and is expected to reach US$ 10,963.26 million by 2030; it is estimated to grow at a CAGR of 14.2% from 2022 to 2030.

Increase in Cases of Lung Cancer Drive Asia Pacific Lung Cancer Therapy Market

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. As per the Cancer Australia 2023 report, ~14,529 new lung cancer cases were diagnosed in 2022; 7,707 were males and 6,822 were females. Nearly 9% of registered new cancer cases were diagnosed in 2022, with an estimated 8,664 deaths from lung cancer. Also, according to studies from the Indian Council of Medical (ICMR), the number of lung cancer cases in India is expected to increase by more than seven times by 2025 when compared to the same period a decade earlier. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

Asia Pacific Lung Cancer Therapy Market Overview

China has experienced the increasing prevalence of lung cancer over the past few years owing to the various factors including smoking, tobacco consumption, and others. As per the International Agency for Research on Cancer reported that approximately 820,000 new lung cancer diagnoses and 715,000 lung cancer-related deaths occurred in China in 2020. A few of the primary causes of lung cancer in China include tobacco use, radiation exposure, family history, and the presence of chronic lung diseases. Further, image-guided percutaneous lung ablation has proven to be an effective alternative approach for the treatment of lung cancer and other lung malignancies.

Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Lung Cancer Therapy Market Segmentation

The Asia Pacific lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Asia Pacific lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Asia Pacific lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Asia Pacific lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Asia Pacific lung cancer therapy market is segmented into China, Japan, India, Australia, South Korea, Southeast Asia, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Asia Pacific lung cancer therapy market.

Product Code: BMIRE00029872

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Asia Pacific Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - Asia Pacific Market Analysis

5.1 Asia Pacific Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Asia Pacific Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Lung Cancer Therapy Market - Country Analysis

9.1.1 Asia Pacific Asia Pacific Lung Cancer Therapy Market, by Country
- 9.1.1.1 China
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 China: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 China: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 China: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 China: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 China: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Japan
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Japan: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Japan: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Japan: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Japan: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Japan: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 India
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 India Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 India: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 India: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 India: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 India: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.4 Australia
  - 9.1.1.4.1 Overview
  - 9.1.1.4.2 Australia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.4.3 Australia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.4.3.1 Australia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.4.4 Australia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.4.5 Australia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.5 South Korea
  - 9.1.1.5.1 Overview
  - 9.1.1.5.2 South Korea: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.5.3 South Korea: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.5.3.1 South Korea: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.5.4 South Korea: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.5.5 South Korea: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.6 Southeast Asia
  - 9.1.1.6.1 Overview
  - 9.1.1.6.2 Southeast Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.3 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.3.1 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.4 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.5 Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.6 Singapore
  - 9.1.1.6.6.1 Singapore: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.6.2 Singapore: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.6.2.1 Singapore: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.6.3 Singapore: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.6.4 Singapore: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.7 Malaysia
  - 9.1.1.6.7.1 Malaysia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.7.2 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.7.2.1 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.7.3 Malaysia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.7.4 Malaysia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.8 Indonesia
  - 9.1.1.6.8.1 Indonesia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.8.2 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.8.2.1 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.8.3 Indonesia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.8.4 Indonesia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.9 Vietnam
  - 9.1.1.6.9.1 Vietnam: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.9.2 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.9.2.1 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.9.3 Vietnam: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.9.4 Vietnam: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.10 Cambodia
  - 9.1.1.6.10.1 Cambodia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.10.2 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.10.2.1 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.10.3 Cambodia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.10.4 Cambodia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.11 Philippines
  - 9.1.1.6.11.1 Philippines: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.11.2 Philippines: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.11.2.1 Philippines: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.11.3 Philippines: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.11.4 Philippines: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 9.1.1.6.12 Rest of Southeast Asia
  - 9.1.1.6.12.1 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.12.2 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.12.2.1 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.12.3 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.12.4 Rest of Southeast Asia: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.7 Rest of Asia Pacific
  - 9.1.1.7.1 Overview
  - 9.1.1.7.2 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.7.3 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.7.3.1 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.7.4 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.7.5 Rest of Asia Pacific: Asia Pacific Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Asia Pacific Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms